Jordan, K., Kinitz, I., Voigt, W., Behlendorf, T., Wolf, H., & Schmoll, H. (2009). Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. European Journal of Cancer, 45, 1184–1187.doi: 10.1016/j.ejca.2008.11.046
To determine the role of an neurokinin 1 (NK1) antagonist in multiple-day chemotherapy, in addition to standard of a 5-HT3 receptor antagonists and dexamethasone
Oral aprepitant 125 mg was given 1 hour before chemotherapy on day 1 and 80 mg oral aprepitant was given daily during chemotherapy and for 2 days after completion of the treatment course. Patients also received 1 mg IV granisetron and 8 mg IV dexamethasone daily prior to chemotherapy. Use and choice of rescue medication was at the discretion of the physician.
The setting was a single site in Germany.
Patients were in active treatment.
The study design was a prospective trial.
Aprepitant appears to be well-tolerated. CR rates were only slightly above those commonly seen with 5-HT3 receptor antagonists and dexamethasone.
Further well-defined research to fully evaluate multiple drug chemotherapy-induced nausea and vomiting regimens is warranted.